Molecular Templates, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity - Additional Information (Detail)

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands							1 Months Ended			12 Months Ended
	Aug. 07, 2020	Nov. 25, 2019	Sep. 25, 2018	Feb. 28, 2018	Aug. 01, 2017	Jun. 23, 2017	Feb. 28, 2021	Jul. 31, 2020	Dec. 31, 2017	Dec. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock										0	0
Net proceeds from common stock										$ 0	$ 71,145
Preferred stock, par value										$ 0.001	$ 0.001
Sale of securities	$ 300,000
Series A Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of shares sold		250
Shares issued, price per share		$ 8.00
Preferred stock, conversion basis										Each share of Series A Preferred Stock is convertible to 1,000 shares of Common Stock, provided that the holder of Series A Preferred Stock will be prohibited from converting the Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding.
Number of preferred stock converted into common stock		1,000
Minimum holding percentage of common stock issued and outstanding upon conversion		9.99%
Preferred stock, par value		$ 0.001
Preferred Stock , voting rights description										The Series A Preferred Stock has no voting rights, except as required by law and except that the consent of the Series A Preferred Stockholders will be required to amend the terms of the Series A Preferred Stock.
Preferred stock beneficial conversion feature intrinsic value		$ 700
Common Stock \| Term Loan Facility \| Perceptive Credit Facility
Class Of Warrant Or Right [Line Items]
Warrant exercisable period				7 years
Common stock exercise price				$ 9.58
Valuation of equity classified warrants recorded in additional paid-n capital				$ 1,500
Expected dividend rate				0.00%
Expected volatility				105.00%
Risk free interest rate				2.80%
Expected term				7 years
Number of shares to be issued upon exercise of warrant				190,000
Wedbush Agreement
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital									$ 400
Expected dividend rate									0.00%
Expected volatility									108.00%
Risk free interest rate									2.30%
Expected term									7 years
Takeda Pharmaceuticals Inc
Class Of Warrant Or Right [Line Items]
Aggregate purchase price						$ 20,000
Each unit of shares transaction of common stock						2,922,993
Purchase price per share						$ 6.8423
Vertex Pharmaceuticals Inc
Class Of Warrant Or Right [Line Items]
Aggregate purchase price						$ 15,000
Each unit of shares transaction of common stock						1,666,666
Purchase price per share						$ 9.00
Private Placement \| Common Stock
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital					$ 16,300
Expected dividend rate					0.00%
Expected volatility					147.00%
Risk free interest rate					2.07%
Expected term					7 years
Private Placement \| Longitude Venture Partners III, L.P.
Class Of Warrant Or Right [Line Items]
Number of aggregate units sold					5,793,063
Aggregate purchase price					$ 40,000
Each unit of shares transaction of common stock					1
Warrants to purchase shares of common stock					0.5
Sale of units, description and its composition										the Company sold an aggregate of 5,793,063 units (the “Units”) having an aggregate purchase price of $40.0 million (“PIPE Financing”), each such Unit consisting of (i) one (1) share (the “Shares”) of our common stock and (ii) a warrant (the “Private Placement Warrants”) to purchase 0.5 shares of our common stock (the “Private Placement”).
Purchase price per unit					$ 6.9048
Warrant exercisable period					7 years
Common stock exercise price					$ 6.8423
Private Placement \| Longitude Venture Partners III, L.P. \| Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock										2,896,528
Private Placement \| Wedbush Agreement \| Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock									57,930	57,930
Warrant exercisable period									7 years
Common stock exercise price									$ 6.8423
Underwritten Public Offering
Class Of Warrant Or Right [Line Items]
Number of shares sold			9,430,000
Shares issued, price per share			$ 5.50
Net proceeds from common stock			$ 48,100
Over Allotment Option
Class Of Warrant Or Right [Line Items]
Number of shares sold		900,000	1,230,000
2019 Underwritten Public Offering
Class Of Warrant Or Right [Line Items]
Number of shares sold		6,900,000
Shares issued, price per share		$ 8.00
Net proceeds from common stock		$ 53,400
At-the-market Offering
Class Of Warrant Or Right [Line Items]
Net proceeds from common stock	$ 100,000							$ 48,500
Gross proceeds from common stock								$ 50,000
Sale of securities											$ 71,145
At-the-market Offering \| Common Stock
Class Of Warrant Or Right [Line Items]
Number of shares sold											6,000,000
Sale of securities											$ 6
At-the-market Offering \| Common Stock at Purchase Price of $12.00 Per Share
Class Of Warrant Or Right [Line Items]
Purchase price per share								$ 12.00
Number of shares sold								3,600,000
At-the-market Offering \| Common Stock at Purchase Price of $12.70 Per Share
Class Of Warrant Or Right [Line Items]
Purchase price per share								$ 12.70
Number of shares sold								500,000
Public Offering
Class Of Warrant Or Right [Line Items]
Number of shares sold							6,000,000.0
Shares issued, price per share							$ 12.65
Net proceeds from common stock							$ 71,100